NextCell Pharma publishes Interim Report 3 2021/2022

July 28, 2022

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period September 1, 2021 – May 31, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report.NextCells share is traded on Nasdaq First North Growth Market under the ticker"NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Third quarter (2022-03-01 until 2022-05-31)

● Operating income amounted to 1 636 (906) TSEK.

● Operating result amounted to -9 307(-6 457)TSEK.

● Earnings per share* amounted to -0,27 (-0,19)SEK.

● Cash and bank amounted to 107 054 (150 754)TSEK.

● Solidity** amounted to 93,5 (96,9) %.

First nine months (2021-09-01 till 2022-05-31)

● Operating income amounted to 4 824 (3 074) TSEK.

● Operating result amounted to -25 991 (-20 079)TSEK.

● Earnings per share* amounted to -0,22 (-0,69)SEK.
‍

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2021/2022: 34,379,523(34,056,943) shares. Average number of shares for the first nine months2021/2022: 34,379,523 (29,074,754) shares. Number of shares in NextCell as of May31, 2022: 34,379,523 (34,379,523) shares.

**Solidity: Own capital's share of the sheet total

Significant events in the third quarter

● NextCell announced in early April that the stemcell bank Cellaviva has disclosed stem cells from umbilical cord blood to Rigshospitalet, Denmark's premier hospital. A sibling of the child whose umbilical cord blood was saved in Cellaviva's biobank, suffers from a serious blood disorder to be treated with stem cells at the Hematology Department at Rigshospitalet.

● NextCell announced in early April that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years
‍
● NextCell announced at the end of April that it is participating in a conference for world-leading cell therapies, the International Society for Cell and Gene Therapy 2022, in San Francisco and is represented by Mathias Svahn, CEO. Dr Svahn is a member of the Business Development and Finance Committee of ISCT.

● NextCell announced at the end of May that the company is presenting the ongoing clinical trial program with the drug candidate ProTrans lead cell therapy at the Advanced Therapies Congress in London on May 24-25.

● NextCell announced at the end of May that the European Patent Office(EPO) had issued an advance grant notice of the patent entitled "Allogeneic Composition" (publication numberEP3752598). The patent describes the method of manufacturing the drug candidate ProTrans and where the selection algorithm for selecting optimal cells and donors is the core. Patent protection is valid up to and i 2039.

Significant events after the reporting period

● NextCell announced in early June that all six children in the first part of the study with ProTrans. Patients will be monitored during the summer after which the safety of the treatment will be evaluated by an independent safety committee.

‍
This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 28-07-2022 07:30 CET.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Websites:
www.nextcellpharma.com
www.cellaviva.se
www.cellaviva.dk

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

Instagram: https://www.instagram.com/cellaviva/

‍

About NextCell Pharma AB

NextCell is a phase II cell therapy company with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to take ProTrans to market approval via a Phase III study. ProTrans is in addition to diabetes, used in two clinical trials for Covid-19, in Örebro and Montreal (Canada). The company is in the processes of establishing its own GMP facility for production of ProTrans. The GMP facility is expected to be ready for production of smaller quantities of ProTrans in 2023. NextCell furthermore owns 8,5% in FamicordTX, a CAR-T start-up in oncology and 100 % of Cellaviva, Scandinavia's largest stem cell bank for family saving stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍

Download attachment Read full press release on Cision (external link)

2018-11-05

Application for clinical trial submitted to the Medical Products Agency, ProTrans-2.

NextCell Pharma AB ("NXTCL") today announced that a new application to conduct a clinical trial with ProTrans has been submitted to the Swedish Medical Products Agency. The purpose of the study is to evaluate repeated treatment with ProTrans, including patients with type 1 diabetes who participated in the dose escalating part of the original NXTCL trial. The ongoing clinical trial called ProTrans-1, was initiated with a dose escalation phase for 9 patients all followed for 12 months. After their last visit in the study, patients will be asked if they want to participate in a new study where

Read more Read more

2018-11-02

Update regarding targeted new issue to Nordic Tech House

NextCell Pharma (NXTCL), announces today that the Board, with the authorization of the Annual General Meeting of December 5, 2017, has decided to implement a directed new issue of Nordic Tech House AB ("NTH") of a maximum of approximately SEK 1.5 million. The reasons for the deviation from shareholders' pre-emption rights are to fulfil the company's commitment in accordance with an agreement with Nordic Tech House AB, which was concluded to provide the company with new owners of strategic importance. Current decision replaces previous resolutions on directed new issue from March 13, 2018,

Read more Read more

2018-10-31

Publication of year-end report

NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its year-end report for book year 2017/2018 (September 2017 – August 2018). Twelve Months (2017-09-01 until 2018-08-31) · Net sales amounted to SEK 655 413 (517 203). · Operating result amounted to SEK –14 032 294 (-13 245 206). · Result per share amounted to SEK -0,61 (-0,64). · Cash and bank amounted to SEK 3 115 876 (16 600 937). · Solidity amounted to 59 (88) %. · Net sales amounted to SEK 127 868 (198 765). · Operating result amounted to SEK -3 422 282 (-4 757 996).

Read more Read more

2018-10-25

The Safety Committee recommends proceeding with part 2 of the stem cell trial in type 1 diabetes

The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Data and Safety Monitoring Board recommends Professor Per-Ola Carlsson Academic Hospital, Uppsala University and NXTCL to proceed with the second part of the clinical trial with ProTrans. Patients with type 1 diabetes aged 18-40 years old who had the disease for a maximum of 2 years and who have some own insulin production are candidates to be included in the study. The second part of the ProTrans trial is a Phase-II study with the aim to further evaluate the efficacy and safety of ProTrans. The efficacy of the

Read more Read more

2018-10-01

NXTCL’s Cellaviva brand is expanding into Denmark

NextCell Pharma AB ("NXTCL") announced today, that the Cellaviva brand will expand its operations into Denmark. As of 1st October 2018, Cellaviva will offer family stem cell banking there. The idea of family saving of stem cells is already an established business in Denmark and NXTCL estimates that its entrance into Denmark will allow for a doubling of annual sales for Cellaviva. The establishment fits within the existing budget and does not affect NXTCL's capital requirements. Cellaviva has now decided to expand its operations to Denmark as of 1st October 2018. The company holds all the

Read more Read more

2018-09-20

Redeemed warrants are now registered with the Swedish Companies Registration Office

NextCell Pharma AB ("NXTCL") announced today, 20th September 2018, that the exercised series TO 1 warrants, whose subscription period ended on 13th September 2018, have now been registered with the Swedish Companies Registration Office. A total of 2 720 931 new shares have been registered, which means that the number of shares in NXTCL after registration amounts to 11 226 356. The share capital amounts to SEK 2 301 402.98. Conversion of interim shares to shares is expected to take place on 28th September 2018. Different agents may take a different amount of time to convert, which means that

Read more Read more

2018-09-17

NXTCL is allocated approximately SEK 12.9 million through redemption of warrants

During the period 23rd August – 13th September 2018, holders of series TO 1 warrants in NextCell Pharma AB ("NXTCL") have been able to subscribe for shares on the basis of their warrants. In total 2 720 931 warrants of series TO 1 were exercised, which means a subscription rate of 95.11 percent. NXTCL is therefore allocated approx. SEK 13.6 million before issue costs, which are estimated to amount to approx. SEK 0.7 million. CEO Mathias Svahn comments "I would like to thank all of those who have shown - and continue to show - their interest and trust in the stem cell company NXTCL. We

Read more Read more

2018-09-11

NextCell to present status of ongoing clinical trial at the Nordic Life Science Days

Stem cell company NextCell Pharma AB ("NXTCL") today presents a status update of its ongoing Phase I/II trial with ProTrans for the treatment of type 1 diabetes. Two out of three patients in the high dose cohort have now undergone treatment and the third patient is scheduled for treatment later this week. NXTCL's clinical trial is divided into two parts, the first part is a three-step dose escalation phase with three patients in each cohort, a total of nine patients. The second part of the trial is randomized, double-blind and placebo-controlled, with ten patients receiving ProTrans and five

Read more Read more